Showing 132 news articles about Injectable & long-acting HIV treatment

Filters Content type: Editors' picks Topic: Injectable & long-acting HIV treatment

Research into injectable medications and other innovative forms of HIV treatment. It is hoped that they may only need to be taken every few weeks or months, rather than daily.

 

Injectable & long-acting HIV treatment

A Long-Lasting, More Effective HIV Drug Is A Psychological Relief For Patients

Editor's pick
NPR
20 November 2020
Injectable & long-acting HIV treatment

ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV

Editor's pick
ViiV Healthcare press release
16 October 2020
Injectable & long-acting HIV treatment

ViiV Healthcare presents positive data from first-ever implementation research study on how best to integrate an investigational once-monthly injectable HIV treatment in US healthcare practices

Editor's pick
ViiV press release
4 July 2020
Injectable & long-acting HIV treatment

GSK says it is within weeks of resubmitting HIV injection Cabenuva

Editor's pick
Reuters
3 July 2020
New & experimental HIV treatments

Experimental HIV drug seems effective at a twice-a-year dose, study finds

Editor's pick
STAT
2 July 2020
Injectable & long-acting HIV treatment

Women With HIV Interested in Long-Acting Injectable Treatment

Editor's pick
POZ
4 May 2020
Injectable & long-acting HIV treatment

Health Canada okays GSK unit's monthly HIV injection

Editor's pick
Reuters
23 March 2020
Injectable & long-acting HIV treatment

Unitaid invests in long-acting medicines to simplify treatment and prevention for HIV, TB, malaria and HCV

Editor's pick
Unitaid
7 February 2020
Injectable & long-acting HIV treatment

No holiday gift for GSK: FDA sends long-acting HIV injectable back to work

Editor's pick
FiercePharma
24 December 2019
Injectable & long-acting HIV treatment

FDA Defers Approval of First Long-Acting HIV Therapy, Surprising Everyone

Editor's pick
HIV and ID Observations
23 December 2019
HIV treatment

Top 10 HIV Clinical Developments of 2019

Editor's pick
TheBodyPro
27 November 2019
New & experimental HIV treatments

ViiV Healthcare announces exclusive licensing agreement with the National Institutes of Health for investigational "bNAb" with potential for long-acting HIV treatment and prevention

Editor's pick
ViiV Healthcare press release
21 November 2019
Injectable & long-acting HIV treatment

Women Find Long-Acting Injectable ART 'Emotionally Freeing and Empowering'

Editor's pick
Contagion Live
7 October 2019
Injectable & long-acting HIV treatment

HIV implant targets disease for up to a year

Editor's pick
The Engineer
26 September 2019
PrEP science

Long-acting injectable multi-drug implant shows promise for HIV prevention and treatment

Editor's pick
EurekAlert
23 September 2019
Injectable & long-acting HIV treatment

DURECT and Gilead Enter into License Agreement for Long-Acting Injectable HIV Investigational Product

Editor's pick
DURECT press release
6 August 2019
People with limited treatment options

Clinical and Economic Effects of Ibalizumab for Multidrug-Resistant HIV

Editor's pick
Infectious Disease Advisor
2 August 2019
Injectable & long-acting HIV treatment

ViiV Healthcare submits regulatory application to EMA for the first monthly, injectable treatment for HIV

Editor's pick
ViiV press release
30 July 2019
People with limited treatment options

EMA panel recommends ibalizumab for multidrug-resistant HIV-1

Editor's pick
Medscape (requires free registration)
30 July 2019
Injectable & long-acting HIV treatment

ViiV Healthcare announces start of first-ever study to identify and evaluate approaches to implementing its once-monthly injectable HIV treatment in clinical practice

Editor's pick
ViiV Healthcare press release
11 July 2019
Injectable & long-acting HIV treatment

Lyndra Therapeutics and Gilead Sciences to Collaborate on Development of Ultra-Long-Acting HIV Therapeutics

Editor's pick
Lyndra Therapeutics press release
10 July 2019
Injectable & long-acting HIV treatment

Study Finds Long-Acting HIV Meds Are Acceptable to Many People, but Differences Exist Among Groups

Editor's pick
The Body Pro
25 June 2019
Injectable & long-acting HIV treatment

NIH Trial Evaluates Long-acting HIV Medication Unable to Adhere to Strict Daily Regimens

Editor's pick
National Institute of Allergy and Infectious Diseases
9 May 2019
Injectable & long-acting HIV treatment

ViiV Healthcare submits New Drug Application to US FDA for the first monthly, injectable, two-drug regimen of cabotegravir and rilpivirine

Editor's pick
ViiV press release
29 April 2019